News - biopix-t

10.01.23

Season’s greetings with a new funding round for all!

From all of us at BIOPIX-T, we very much hope you have a Happy, Healthy and Successful New Year 2023!!!
We are about to launch a public bridge financing round in the coming weeks, followed by a full Series A round within the next two years. This bridge round will be funded by a combination of institutional investors who have already committed the majority of the necessary funds and a public crowdfunding campaign. All information about the terms and our future plans can be found by following this link: https://investors.seedblink.com/landing/2817c463e2c5f9c6 .

28.07.22

BIOPIX-T to participate in a H2020-RIA project granted for the early detection of Sepsis at the point-of-care!

We are pleased to announce that BIOPIX-T is participating as a design and commercialization partner, in a grant that was awarded to a consortium of 12 esteemed research institutions and companies, with the aim to develop a point-of-care device for the early detection of Sepsis.

20.06.22

BIOPIX-T voted by judges as top presenter in Tech Tour South East Europe 2021-2022

We are super-excited to announce that we have been selected as a winner of the 2021-2022 Tech Tour South East Europe Program after 2 rounds of intensive and competitive pitching sessions in Athens in May and online in June!

06.06.22

PEBBLE achieves IVDR declaration

Another important milestone achieved! Our declaration of conformity as per IVDR, for the PEBBLE qcLAMP Platform, was today approved by the Greek Organization for Medicines! We are one of the first companies in Greece to achieve the IVDR compliance for one of its products! Congratulations to all the BIOPIXers whose hard work and dedication led to this achievement!!!

08.03.22

Portable real-time colorimetric LAMP-device for rapid quantitative detection of nucleic acids in crude samples

Finally, the long-awaited research paper detailing the work that was done developing IRIS – the predecessor of PEBBLE – has been published! https://www.nature.com/articles/s41598-022-06632-7 Congratulations to all researchers who contributed to this work but especially to our very own Dr. George Papadakis, Dr. Alexandros Pantazis, Mr. Nikolaos Fikas and Mrs. Stella Chatziioannidou who continue to develop […]

28.02.22

BIOPIX-T completes the technology trasnfer to Kiara Health of South Africa.

What a rewarding week the past week has been! Our team visited our partner Kiara Health in South Africa to complete the technology transfer for the production of the PEBBLE qcLAMP Platform and the COV19 qcLAMP kit!

11.10.21

BIOPIX-T launches its portable molecular diagnostic device “PEBBLE” with the COVID19 test for the point of care!

At BIOPIX-T we are pleased to announce that the portable molecular diagnostic platform “PEBBLE” and its compatible diagnostic test for the detection of Coronavirus are now commercially available! The “PEBBLE qcLAMP Platform“, as its full name is, is the first Greek portable molecular diagnostic device based on LAMP technology (Isothermal PCR), which can be used at the Point-of-Care. It is notified to […]

03.08.21

BIOPIX-T receives the ISO/IEC 27001:2013 certification and expands its ISO 13485:2016

BIOPIX-T (www.biopix-t.com ) is pleased to announce that its information security management system (ISMS) has been certified as per ISO/IEC 27001:2013 by DQS Hellas. Moreover, BIOPIX-T successfully audited for the extension of the scope of its ISO 13485:2016, also by DQS Hellas, to additionally include the “Technical Support” and also cover its new manufacturing premises. Our new certification as per ISO/IEC 27001:2013 confirms […]

16.04.21

Eleven invests in the Greek biotech company BIOPIX-T

After the initial investment from Metavallon.vc, we are exited to be also included in the portfolio of Eleven Ventures, further broadening the institutional support we receive and our geographical footprint! On the investment in BIOPIX-T Valeri Petrov, Partner at Eleven Ventures explains: “BIOPIX-T is our first investment in Greece and the company fits perfectly in one of our […]

03.02.21

BIOPIX-T CERTIFIED AS PER ISO 13485:2016

BIOPIX-T (www.biopix-t.com ) is pleased to announce that its quality management system (QMS) has been successfully certified as per ISO 13485:2016 requirements by DQS Hellas, with scope “Design and Development, Production, Storage and Distribution of nucleic acid amplification kits (COV19 qc LAMP kit and Flu A qc LAMP kit) and instruments (Pebble qc LAMP platform)”. Our ISO 13485:2016 certification serves our mission to offer safe portable In-Vitro diagnostic medical devices […]

27.01.21

10 promising Greece-based startups to watch in 2021!

BIOPIX-T was included in the EU startups list of the 10 promising startups from Greece to watch in 2021! We are among the 10 ‘up and coming’ local startups making a name for themselves, which were founded in the last 1-3 years, show promising signs, landed funding in the last year and are growing their teams […]

18.01.21

Quality Policy

It is the policy of BIOPIX-T to develop, manufacture and market safe and effective products to applicable specifications that meet national and International Standards and Regulatory Requirements […]

27.10.20

Coronavirus SARS-CoV-2 Detection with IRIS

On the 21st of October 2020, the Institute of Molecular Biology and Biotechnology (IMBB) initiated the implementation of a Research Project/Programme aiming at the molecular detection of the SARS-CoV-2 virus in samples coming from volunteers-employees who show no symptoms of an active infection. The target of the research programme is to act as an additional […]

02.09.20

BIOPIX DNA Technology P.C. receives EU funding

BIOPIX-T (www.biopix-t.com ) is pleased to announce that a consortium of eight partners in which it participated, has been awarded EU funding (€2.4M) under the emergency call H2020-SC1-PHE-CORONAVIRUS-2020-2. The aim of the proposal, entitled “Market Release of a Portable Device for COVID-19 at the Point-of-Care; a Global Diagnostics Approach” with the acronym “IRIS-COV”, is the immediate development, certification and release of BIOPIX-T ‘s novel diagnostic platform, IRIS, to carry out a combined test for SARS-CoV–2 and Influenza A. In addition to BIOPIX-T (medical device […]

23.07.20

BIOPIX DNA TECHNOLOGY P.C. won at the John and Mary Pappajohn Business Plan Competition

BIOPIX-T was one of the 5 winners, out of 138 teams that participated in the 7th John and Mary Pappajohn Business Plan Competition, organised by the Entrepreneurship Hub at Anatolia College of Thessaloniki! We would like to thank the organisers for an excellent event, despite the pandemic related constraints, and the judges for believing in […]

20.05.20

BIOPIX DNA TECHNOLOGY P.C. as a member at Hellenic Biocluster

BIOPIX-T is pleased to announce that it has been accepted as a member of the Hellenic Biocluster. Through the networking and collaborations that this membership will facilitate, we expect to accelerate our market entry both in Greece and abroad. We would like to thank the management board of HBio for recognizing our technology and our commercial […]

12.12.19

BIOPIX DNA TECHNOLOGY P.C. is established

We are happy to announce today the official registration of our company! BIOPIX-T aims to revolutionize molecular diagnostics at the Point-Of-Care and Home-Testing environments on a global scale. BIOPIX DNA TECHNOLOGY P.C. is a Spin-Off company from the Institute Of Molecular Biology and Biotechnology (IMBB) at the Foundation of Research and Technology Hellas (FORTH). As a project under the umbrella […]